Skip to content
10-Q

Quarterly Report

Spero Therapeutics, Inc. SPRO

0000950170-25-070380

← back to feed
Filed
May 13, 2025 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2025 · May 1, 2025 55.91M sh
Cash And Equivalents Q1 2025 · Mar 31, 2025 $48.89M
Cash And Equivalents Q1 2025 · Dec 31, 2024 $52.89M
Current Liabilities Q1 2025 · Mar 31, 2025 $29.16M
Current Liabilities Q1 2025 · Dec 31, 2024 $49.07M
Total Liabilities Q1 2025 · Mar 31, 2025 $43.9M
Total Liabilities Q1 2025 · Dec 31, 2024 $64.42M
Current Assets Q1 2025 · Mar 31, 2025 $74.71M
Current Assets Q1 2025 · Dec 31, 2024 $107.28M
Total Assets Q1 2025 · Mar 31, 2025 $77.71M
Total Assets Q1 2025 · Dec 31, 2024 $110.54M
Shares Diluted Q1 2025 · Mar 31, 2024 53.52M sh
Operating Cash Flow Q1 2025 · Mar 31, 2024 $5.94M
Stockholders Equity Q1 2025 · Mar 31, 2024 $96.25M
Stockholders Equity Q1 2025 · Dec 31, 2023 $106.89M
Eps Diluted Q1 2025 · Mar 31, 2024 −$0.24
Eps Basic Q1 2025 · Mar 31, 2024 −$0.24
Sga Expense Q1 2025 · Mar 31, 2024 $5.92M
Rd Expense Q1 2025 · Mar 31, 2024 $17.33M
Net Income restated Q1 2025 · Mar 31, 2024 −$12.67M
Operating Income Q1 2025 · Mar 31, 2024 −$13.98M
Revenue Q1 2025 · Mar 31, 2024 $140K